CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 127 enrolled
Drug / intervention
Degarelixdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01215513
NCT01215513Phase 3Completed
CompareCT.gov

An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients Requiring Androgen Ablation Therapy

Ferring Pharmaceuticals·interventional·Posted Oct 6, 2010·Updated May 22, 2013

In Brief

A Phase 3 clinical trial evaluating Degarelix for Prostate Cancer. Completed, enrolled 127 participants across 11 sites.

Detailed Summary

This is an open-label, multi-centre single arm trial to investigate long-term safety and tolerability of degarelix in Korean patients with prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesSouth Korea
CollaboratorsFerring Pharmaceuticals Korea, Ltd.

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 6, 2010
Enrollment StartSep 1, 2010
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.7 years ago

Interventions

Degarelixdrug